Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Florian Heitz

Showing results (111-120 of 178) with videos related to

Pageof 18
Sort By:
Journal of Comparative Effectiveness Research|December 6, 2024
Use of individualized starting dose and niraparib hematologic adverse event management costs in ovarian cancerWhitney S Graybill, Ignace Vergote, Bhavana Pothuri, et al.
Journal of Gynecologic Oncology|July 1, 2025
Phase III double-blind randomized placebo controlled trial of atezolizumab in combination with carboplatin and paclitaxel in women with advanced/recurrent endometrial carcinoma: the Asian cohort of the AtTEnd/ENGOT-EN7 trialKenichi Harano, Roldano Fossati, Beatriz Pardo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 3, 2025
Atezolizumab With Bevacizumab and Nonplatinum Chemotherapy for Recurrent Ovarian Cancer: Final Results From the Placebo-Controlled AGO-OVAR 2.29/ENGOT-ov34 Phase III TrialPhilipp Harter, Frederik Marmé, Andrés Redondo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 29, 2023
Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 TrialJean-Emmanuel Kurtz, Eric Pujade-Lauraine, Ana Oaknin, et al.
Geburtshilfe Und Frauenheilkunde|April 8, 2025
Sarcoma of the Uterus. Guideline of the DGGG, OEGGG and SGGG (S2k-Level, AWMF Registry No. 015/074, June 2024)Markus Wallwiener, Marco Johannes Battista, Eike-Christian Burandt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 20, 2023
The Prognostic Effect of Immune Cell Infiltration Depends on Molecular Subtype in Endometrioid Ovarian CarcinomasKarolin Heinze, Evan S Cairns, Shelby Thornton, et al.
Geburtshilfe Und Frauenheilkunde|May 19, 2025
Evaluation of Baseline Characteristics and Therapeutic Management Strategies in Metastatic Cervical Cancer in Germany: A Multicentric Retrospective Longitudinal Observational Study: A Quality Assurance Initiative of the AGO-Study Group and AGO-OK UterusDominik Denschlag, Bastian Czogalla, Florian Heitz, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|July 2, 2026
Poly(adenosine diphosphate-ribose) polymerase inhibitor maintenance therapy with niraparib in patients with primary advanced or recurrent endometrial cancer receiving dostarlimab plus chemotherapyMatthew A Powell, Sharad Ghamande, Lars C Hanker, et al.
Plos One|October 21, 2017
Prevalence of deleterious germline variants in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO-TR-1)Philipp Harter, Jan Hauke, Florian Heitz, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|January 11, 2023
Treatment strategies in patients with gynecological sarcoma: Results of the prospective intergroup real-world registry for gynecological sarcoma in Germany (REGSA-NOGGO RU1)Eva Roser, Philipp Harter, Dario Zocholl, et al.
Pageof 18

Showing results (111-120 of 178) with videos related to

Sort By:
Pageof 18
Journal of Comparative Effectiveness Research|December 6, 2024
Use of individualized starting dose and niraparib hematologic adverse event management costs in ovarian cancerWhitney S Graybill, Ignace Vergote, Bhavana Pothuri, et al.
Journal of Gynecologic Oncology|July 1, 2025
Phase III double-blind randomized placebo controlled trial of atezolizumab in combination with carboplatin and paclitaxel in women with advanced/recurrent endometrial carcinoma: the Asian cohort of the AtTEnd/ENGOT-EN7 trialKenichi Harano, Roldano Fossati, Beatriz Pardo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 3, 2025
Atezolizumab With Bevacizumab and Nonplatinum Chemotherapy for Recurrent Ovarian Cancer: Final Results From the Placebo-Controlled AGO-OVAR 2.29/ENGOT-ov34 Phase III TrialPhilipp Harter, Frederik Marmé, Andrés Redondo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 29, 2023
Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 TrialJean-Emmanuel Kurtz, Eric Pujade-Lauraine, Ana Oaknin, et al.
Geburtshilfe Und Frauenheilkunde|April 8, 2025
Sarcoma of the Uterus. Guideline of the DGGG, OEGGG and SGGG (S2k-Level, AWMF Registry No. 015/074, June 2024)Markus Wallwiener, Marco Johannes Battista, Eike-Christian Burandt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 20, 2023
The Prognostic Effect of Immune Cell Infiltration Depends on Molecular Subtype in Endometrioid Ovarian CarcinomasKarolin Heinze, Evan S Cairns, Shelby Thornton, et al.
Geburtshilfe Und Frauenheilkunde|May 19, 2025
Evaluation of Baseline Characteristics and Therapeutic Management Strategies in Metastatic Cervical Cancer in Germany: A Multicentric Retrospective Longitudinal Observational Study: A Quality Assurance Initiative of the AGO-Study Group and AGO-OK UterusDominik Denschlag, Bastian Czogalla, Florian Heitz, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|July 2, 2026
Poly(adenosine diphosphate-ribose) polymerase inhibitor maintenance therapy with niraparib in patients with primary advanced or recurrent endometrial cancer receiving dostarlimab plus chemotherapyMatthew A Powell, Sharad Ghamande, Lars C Hanker, et al.
Plos One|October 21, 2017
Prevalence of deleterious germline variants in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO-TR-1)Philipp Harter, Jan Hauke, Florian Heitz, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|January 11, 2023
Treatment strategies in patients with gynecological sarcoma: Results of the prospective intergroup real-world registry for gynecological sarcoma in Germany (REGSA-NOGGO RU1)Eva Roser, Philipp Harter, Dario Zocholl, et al.
Pageof 18